ASH 2022 Conference Coverage
ASH 2022 Phase 3 ZUMA-7 Study: Outcomes of Subsequent Anti-Lymphoma Therapies in Pts With LBCL Treated With Axi-Cel or SoC in the 2L
By
ASH 2022 Conference Coverage
FEATURING
Armin Ghobadi
By
ASH 2022 Conference Coverage
FEATURING
Armin Ghobadi
Login to view comments.
Click here to Login